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Since 2004, we have developed five phase II trials in
Chronic Lymphocytic Leukaemia (CLL), utilising six dif-
ferent statistical methods. Two of the trials have closed
to recruitment, two are currently open and a further
one is in development. The rationale behind the differ-
ent designs chosen for each trial will be explained. Diffi-
culties and learning experiences with the
implementation, wider understanding and interpretation
of the trials will be discussed.
CLL201 used Gehan’s two-stage approach to assess
response, and randomised to a control arm which was
not included for formal comparison, but to give validity
of the study results. Challenges included the timing of
the stage I analysis without halting recruitment, and the
temptation to formally compare the two arms even
though there was not power to do so. The inclusion of
the control arm proved to be valuable since the
response rates were not as expected.
CLL207 is a single arm trial designed using Bryant and
Day’s two-stage design, incorporating toxicity considera-
tions as well as efficacy. The two-stage aspect worked
well in this trial due to the short treatment duration
and assessment time. However, implementation was dif-
ficult due to the definitions of unacceptable toxicity and
unacceptability bounds, and the overlap with the role of
the Data Monitoring Committee.
ARCTIC and ADMIRE are two large, randomised
phase IIb trials, both formally powered to compare
responses against a common control arm. One of the
trials assesses non-inferiority. Difficulties were experi-
enced in convincing reviewers that these were not
underpowered phase III trials. This design was necessary
for the non-inferiority question, as it provides an accep-
table certainty of finding the treatment inferior in terms
of response before proceeding to a much larger trial to
assess longer-term endpoints.
COSMIC is a randomised selection design with two
experimental arms. The A’Hern one-stage design is used
to determine which of the treatments are eligible to be
taken forward for further investigation. In the case
where both are acceptable, Sargent & Goldberg’ss e l e c -
tion criteria will be applied to determine whether to
take forward the treatment with better response rate, or
to use alternative selection criteria. The sample size was
inflated to ensure acceptable power for selecting the
best treatment.
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